ACAD
37.04
+0.3
+0.82%
AEMD
6.23
-0.06
-0.95%
APRI
0.309
-0.012
-3.8641%
ARNA
1.67
-0.01
-0.60%
ATEC
0.41
+0.03
+7.92%
CNAT
2.26
-0.03
-1.31%
CRXM
0.177
-0.003
-1.667%
CYTX
2.17
+0.12
+5.85%
DXCM
92.23
+2.67
+2.98%
GNMK
10.65
+0.39
+3.80%
HALO
9.94
+0.17
+1.74%
ILMN
166.35
-0.07
-0.04%
INNV
0.54
-0.01
-1.80%
INO
9.88
+0.26
+2.70%
ISCO
1.99
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
134.88
-0.01
-0.01%
LPTN
1.95
-0.05
-2.50%
MBVX
0.6
-0.05
-7.69%
MEIP
1.36
0.00
-0.01%
MNOV
6.2
+0.13
+2.14%
MRTX
4.64
+0.08
+1.75%
MSTX
0.357
-0.006
-1.6249%
NBIX
50.23
+0.08
+0.16%
NUVA
62.2
+0.18
+0.29%
ONCS
1.82
+0.03
+1.68%
ONVO
4.28
-0.01
-0.23%
OREX
3.35
-0.03
-0.89%
OTIC
14.36
-0.1
-0.69%
QDEL
22.8
-0.44
-1.89%
RCPT
231.96
0.00
0.00%
RGLS
3.57
0.00
+0.14%
RMD
68.88
+3.18
+4.84%
SPHS
5.86
+0.46
+8.52%
SRNE
6.29
+0.1
+1.62%
TROV
5.63
+0.18
+3.30%
VICL
4.15
-0.05
-1.19%
VOLC
18
0.00
0.00%
ZGNX
9.13
+0.05
+0.55%
ACAD
37.04
+0.3
+0.82%
AEMD
6.23
-0.06
-0.95%
APRI
0.309
-0.012
-3.8641%
ARNA
1.67
-0.01
-0.60%
ATEC
0.41
+0.03
+7.92%
CNAT
2.26
-0.03
-1.31%
CRXM
0.177
-0.003
-1.667%
CYTX
2.17
+0.12
+5.85%
DXCM
92.23
+2.67
+2.98%
GNMK
10.65
+0.39
+3.80%
HALO
9.94
+0.17
+1.74%
ILMN
166.35
-0.07
-0.04%
INNV
0.54
-0.01
-1.80%
INO
9.88
+0.26
+2.70%
ISCO
1.99
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
134.88
-0.01
-0.01%
LPTN
1.95
-0.05
-2.50%
MBVX
0.6
-0.05
-7.69%
MEIP
1.36
0.00
-0.01%
MNOV
6.2
+0.13
+2.14%
MRTX
4.64
+0.08
+1.75%
MSTX
0.357
-0.006
-1.6249%
NBIX
50.23
+0.08
+0.16%
NUVA
62.2
+0.18
+0.29%
ONCS
1.82
+0.03
+1.68%
ONVO
4.28
-0.01
-0.23%
OREX
3.35
-0.03
-0.89%
OTIC
14.36
-0.1
-0.69%
QDEL
22.8
-0.44
-1.89%
RCPT
231.96
0.00
0.00%
RGLS
3.57
0.00
+0.14%
RMD
68.88
+3.18
+4.84%
SPHS
5.86
+0.46
+8.52%
SRNE
6.29
+0.1
+1.62%
TROV
5.63
+0.18
+3.30%
VICL
4.15
-0.05
-1.19%
VOLC
18
0.00
0.00%
ZGNX
9.13
+0.05
+0.55%
Home » Hugo Villar, Ph.D., MBA-Bio

Hugo Villar, Ph.D., MBA-Bio

Hugo O. Villar Ph.D., MBA is director for Science and Technology programs at UC San Diego Extension. He is also President of Altoris, Inc. a San Diego based specializing in information management for the biotech and pharmaceutical industries and providing consulting on discovery technologies. He was Vice President for Chemoproteomics at Triad Therapeutics and Vice President of Discovery Technologies at Telik, Inc. His work resulted in over 80 publications and 18 patents on the development of technologies for drug discovery. He has a Ph.D. in Chemistry and an MBA with a concentration in Pharmaceuticals and Helathcare.